Adaptive Biotechnologies is trading at $25.20, down 4.13%, with no fresh company-specific catalyst identified amid broader market weakness.
- The decline follows losses on October 6 and 7. Rising Treasury yields and oil prices have weighed on markets; the Nasdaq was down 0.51% in the provided market context.
- Available reports on insider sales and earnings refer to earlier events, not a new October 8 announcement.